You’d think that a widely-ordered test would play a part in management and outcome, but two clotting mutations seem exceptions to that rule. Although often requested, the FDA-approved tests for Factor V Leiden and G20210A mutations don’t seem to figure greatly in case management of venous thromboembolism, at least according to the published literature. Dr. Jodi Segal and her team published a meta-analysis in JAMA this week, and she’s here to discuss the results.

This week’s links:

News–

Interview links–

The post Podcast 46: Does Genetic Testing for Clotting Mutations Matter? An interview with Jodi Segal of Johns Hopkins first appeared on Clinical Conversations.